Individualized dosing: Compounding pharmacies can prepare individualized doses for patients whose clinical needs, as determined by their prescriber, require a formulation not available in an FDA-approved product
Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]
A clearer, brighter complexion with an even tone
Tuesday, the pharma secured an exclusive Chinese commercialization license for Sciwind Biosciences China-approved GLP-1 injection
Under section 503B of the Federal Food, Drug, and Cosmetic Act, large outsourcing facilities may only compound from bulk active ingredients in two situations: the ingredient appears on the 503B bulks list, meaning FDA has found a clinical need for it, or the finished drug sits on FDA's shortage list at the time of compounding